TMCI
Company Description
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 212.69M | 209.36M | 187.12M | 141.84M | 94.42M | 57.37M | 39.42M |
| Net Income | (59.00M) | (55.74M) | (49.53M) | (42.81M) | (20.55M) | (3.67M) | (4.26M) |
| EPS | -0.93 | -0.90 | -0.81 | -0.77 | -0.38 | -0.08 | -0.10 |
| Free Cash Flow | (29.49M) | (48.76M) | (46.03M) | (45.49M) | (19.90M) | (5.56M) | (8.88M) |
| FCF / Share | -0.47 | -0.79 | -0.76 | -0.82 | -0.37 | -0.11 | -0.17 |
| Operating CF | (15.97M) | (37.17M) | (34.58M) | (30.65M) | (17.19M) | (4.49M) | (7.67M) |
| Total Assets | 190.58M | 217.09M | 251.91M | 159.02M | 140.82M | 41.81M | 29.72M |
| Total Debt | 13.98M | 69.65M | 70.30M | 68.59M | 29.36M | 30.98M | 19.22M |
| Cash & Equiv | 10.71M | 11.35M | 12.98M | 19.47M | 105.83M | 18.08M | 12.14M |
| Book Value | 87.33M | 112.89M | 137.94M | 60.53M | 93.07M | 776,000 | 3.16M |
| Return on Equity | -0.68 | -0.49 | -0.36 | -0.71 | -0.22 | -4.73 | -1.35 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 47.20M | 62.52M | 50.21M | 47.39M | 52.57M | 68.71M | 45.09M | 44.45M | 51.11M | 62.21M | 40.76M | 41.95M |
| Net Income | (17.96M) | (9.39M) | (16.29M) | (17.40M) | (15.92M) | (501,000) | (15.36M) | (21.21M) | (18.68M) | (6.28M) | (17.52M) | (12.27M) |
| EPS | -0.28 | -0.15 | -0.26 | -0.28 | -0.25 | -0.01 | -0.25 | -0.34 | -0.30 | -0.10 | -0.28 | -0.20 |
| Free Cash Flow | 4.17M | (10.42M) | (11.90M) | (7.82M) | 655,000 | (7.28M) | (14.71M) | (15.63M) | (11.15M) | (1.72M) | (13.01M) | (12.57M) |
| FCF / Share | 0.06 | -0.16 | -0.19 | -0.12 | 0.01 | -0.12 | -0.24 | -0.25 | -0.18 | -0.03 | -0.21 | -0.20 |
| Operating CF | 7.23M | (8.03M) | (9.09M) | (3.05M) | 4.20M | (4.21M) | (11.84M) | (13.90M) | (7.22M) | 532,000 | (9.51M) | (8.34M) |
| Total Assets | 184.10M | 190.58M | 196.59M | 206.44M | 205.85M | 217.09M | 212.92M | 226.08M | 242.73M | 251.91M | 240.36M | 249.64M |
| Total Debt | 13.55M | 13.98M | 70.37M | 70.09M | 69.36M | 69.65M | 70.12M | 69.85M | 70.11M | 70.30M | 70.49M | 69.62M |
| Cash & Equiv | 9.54M | 10.71M | 7.69M | 8.05M | 13.37M | 11.35M | 12.11M | 18.18M | 9.33M | 12.98M | 7.28M | 12.04M |
| Book Value | 77.19M | 87.33M | 89.19M | 97.61M | 105.34M | 112.89M | 104.91M | 112.14M | 126.39M | 137.94M | 137.86M | 149.96M |
| Return on Equity | -0.23 | -0.11 | -0.18 | -0.18 | -0.15 | -0.00 | -0.15 | -0.19 | -0.15 | -0.05 | -0.13 | -0.08 |
